Issue No. 04 · 2026

Decades, Not Months

What science shows about the longevity of cell and adipose tissue cryopreservation · References: PubMed / PNAS / Stem Cells Translational Medicine / Scientific Reports
Executive Summary

The most common question patients and physicians ask about LipAge: 'How long does stored material retain its clinical utility?'

• Hematopoietic cells: functional viability documented for up to 34 years of cryopreservation (ScienceDirect, 2025). • Umbilical cord blood: stability validated for up to 29 years (Stem Cells Transl Med, 2024). • Adipose tissue ASCs: 78% viability after 10+ years — identical to the 3–7-year group (Scientific Reports, 2018). • Intact adipose tissue: average volume recovery of 67–71% after up to 44 months, with no negative correlation with time.

34
years — longest documented duration with viable CD34+HSPCs
29
years — validated cord blood bank stability (José Carreras)
78%
post-thaw ASC viability after 10+ years
95%
mesenchymal marker expression (CD90/CD105/CD73) after 10 years
01

The Physics of Cryopreservation — Why Time Does Not Age Cells

Cryopreservation in liquid nitrogen at -196°C completely suspends cellular metabolic activity. Below -130°C, molecular motion is virtually absent: there is no protein synthesis, no ATP consumption, no cell division, and no oxidation.

🌡 The Critical Window in Cryopreservation

Cellular damage during cryopreservation does not occur after months or years of storage — it occurs during the first and last minutes of the process:

• Freezing: intracellular ice crystals form within the -15°C to -60°C range. Controlled cooling (1–2°C/min) and cryoprotectants (DMSO) prevent this damage.

• Storage: below -130°C, there is no detectable change. Time itself is not a factor in degradation.

• Thawing: rapid warming (37°C water bath) is critical to preventing recrystallization.

02

Timeline of Scientific Evidence — From Theory to 34 Years

1980sFirst studies of hematopoietic cell cryopreservation. Broxmeyer HE begins a longitudinal series using umbilical cord blood samples.
2003Broxmeyer et al. (PNAS): functional recovery of progenitor cells after 15 years. Average recovery >83% of nucleated cells, >95% CFU-GM.
2011Broxmeyer et al. (Blood): viability and iPS generation from samples cryopreserved for 21–23.5 years.
2018Shaik et al. (Sci Reports): ASCs >10 years vs. 3–7 years — viability 78% vs. 79%, with no significant difference. CD90/CD105/CD73 >95% in both.
2019Bucky & May (PMC6463172): intact lipoaspirate, 194 samples — average volume recovery of 67%, storage for up to 44 months without decline.
2024Liedtke et al. (Stem Cells Transl Med): José Carreras Bank — 29 years with no change in TNC or CD34+.
2025Lysak et al. (ScienceDirect): 30 samples stored for up to 34 years — no quality marker differed between the first and second decades.
03

Real Risks vs. the Myth of Time

⛔ MythTime in liquid N₂ storage (-196°C) alone degrades cells. There is no evidence of time-related degradation when the temperature is maintained.
⚠ Risk #1Temperature fluctuations: any warming above -130°C initiates residual metabolic activity and recrystallization damage.
⚠ Risk #2Freezing process: ice crystals form within the -15°C to -60°C range. Uncontrolled cooling causes irreversible damage.
⚠ Risk #3Improper thawing: slow warming recreates the crystallization window. A 37°C water bath protocol is mandatory.
⚠ Risk #4Contamination during collection: 29% of samples arrive contaminated. This — not time — poses the greatest risk of rendering the material unusable.
04

What Can and Cannot Be Said to Patients

✅Studies published in indexed scientific journals show that adipose-derived stromal cells (ASCs) retain viability and mesenchymal characteristics for more than 10 years of cryopreservation in liquid nitrogen.
✅Cryopraxis operates with 24/7 monitoring, redundant cryogenic systems, and AABB accreditation — the same infrastructure standards used by the banks that conducted these studies.
❌A guarantee of X years of viability for a patient's specific material — no bank can guarantee the future without ongoing prospective monitoring.
❌That cell viability guarantees a clinical outcome — viability is a necessary but insufficient condition for clinical efficacy.

References

  1. Lysak D et al. Long-term cryopreservation of hematopoietic stem and progenitor cells. Cytotherapy. 2025.
  2. Liedtke M et al. Long-term stability of cord blood units after 29 years. Stem Cells Transl Med. 2024;13(1):30–40. doi:10.1093/stcltm/szad075.
  3. Broxmeyer HE et al. 21–23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773–4777.
  4. Broxmeyer HE et al. 15-year cord blood study. PNAS. 2003;100(2):645–650.
  5. Shaik S et al. Effects of decade long freezing storage on adipose derived stem cells. Sci Rep. 2018;8(1):8162.
  6. Domenis R et al. Long-Term Biobanking of Intact Tissue from Lipoaspirate. Aesthet Surg J. 2019. PMC6463172.
  7. Meneghel J et al. Cryopreservation as a Key Element in Cell-Based Therapies. Front Med. 2020. PMC7727450.